FAQ

Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly. It is a triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors, and it is being studied in Phase 3 clinical trials.

Retatrutide is still investigational, so its long-term safety profile is not yet fully established. In clinical trials, reported adverse events have included gastrointestinal symptoms such as nausea, diarrhea, constipation, decreased appetite, and vomiting; most were mild to moderate and resolved during treatment.

Retatrutide activates GIP, GLP-1, and glucagon receptors. In preclinical and early clinical research, it has been associated with reduced food intake, increased energy expenditure, and potential improvements in glucose and lipid metabolism.
Retatrutide Core provides retatrutide for in-vitro laboratory research only. These mechanisms are research findings and do not constitute guidance for human use.

You can buy retatrutide online for laboratory research directly from Retatrutide Core. We supply research-use-only retatrutide to qualified researchers and institutions worldwide.
Our products are intended strictly for in-vitro laboratory research and are not for human consumption, self-injection, or personal use.

In clinical research, measurable effects have generally been observed over weeks to months. In a 48-week Phase 2 trial, retatrutide produced significant weight reduction by 24 weeks, with greater changes reported at 48 weeks.

Retatrutide works by activating three receptors: GLP-1, GIP, and glucagon. This triple action may influence appetite, gastric emptying, insulin secretion, glucose regulation, fat metabolism, and energy expenditure.

Retatrutide Core products are supplied for laboratory research use only and are not intended to be taken by humans. We do not provide dosing, injection, or self-administration instructions.
In clinical trials, retatrutide was studied as a once-weekly subcutaneous injection under medical supervision, but this does not constitute guidance for personal use.

Retatrutide isn’t in pharmacies yet, so the only place to buy it right now is online — either from research-peptide suppliers or from compounding pharmacies. You can order directly from Retatrutide Core, dispatched from the EU and shipped worldwide, with a batch-matched certificate of analysis on every vial. Always check third-party testing before buying anywhere.

Yes — but mostly indirectly. Retatrutide doesn’t act like a thermogenic fat burner; it suppresses appetite heavily and its glucagon-receptor activity raises energy expenditure and lipolysis, so the deficit does the work. Trial data shows the loss is predominantly fat mass rather than muscle, which is why it outperforms GLP-1-only drugs.

Subcutaneously, into the abdomen, front of the thigh, or the back of the upper arm — the same sites used in the trials. In the abdomen, stay at least 5 cm clear of the navel. Rotate the site each week to prevent lumps and lipohypertrophy, and never inject into the same spot twice in a row.